Acute Hyperbaric Oxygen (HBO) Treatment Increases Hepatic Insulin Sensitivity and Muscle Reactive Oxygen Species in Type 2 Diabetes
Description:
In total 14 patients are planned. Each participant participates in both experimental parts
(100% O2 and ambient air). They are examined immediately after each HBO/ ambient air therapy.
The allocation is randomized treated every three weeks with 2-hour therapies using pure O2 or
indoor air. Randomized and double-blinded in a cross-over setting, one group of patients with
type 2 diabetes is first treated with HBO therapy and the other group is first treated with
room air. Here, an ambient pressure of 2.4 ATM is built up and then administered for
respiration over a total of 90 minutes of pure O2. Patients are examined on two consecutive
days for each part of the study.On the first day serum samples are taken and a sample is
taken from the vastus lateralis muscle. A magnetic resonance spectroscopic examination (MRS)
is performed on the patient subsequently. In this case, phosphorus metabolites (absolute
quantification of ATP, Pi) and the ATP synthase flow rate (fATP) are determined
non-invasively by means of 31P MRS and TG storage (HCL) by means of 1H-MRS.
On the next day of the trial patients are treated with HBO therapy or room air. A
hyperinsulinemic-euglycemic clamp test (120-300 min) with administration of deuterated
glucose (D- [6,6-2H2] glucose) (0-120 min) to measure muscular and hepatic insulin resistance
will be performed after the end of HBO therapy or room air treatment performed. Indirect
calorimetry determines energy consumption and substrate selection (lipid and glucose
oxidation) in hyperinsulinaemia. After the end of the HBO therapy or room air treatment and
30 minutes after the start of the clamp test, a sample is taken from the vastus lateralis
muscle again.
Condition:
Type 2-diabetes
Treatment:
hyperbaric oxygen chamber
Start Date:
February 1, 2020
Sponsor:
German Diabetes Center
For More Information:
https://clinicaltrials.gov/show/NCT04219215